drugset / Trial / NCT05439460

Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension

NCT05439460

Phase 4 Completed 15 enrolled Stanford University
Non-randomizedSequentialOpen-labelTreatment

Summary

Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the pulmonary arteries (PAP) is high. PAH increases the risk of adverse events, including death, during and or after procedures. The severity of baseline PAH correlates with the incidence of major complications, such that those with PAP higher than their systemic blood pressure (SBP) had a 8 fold increased risk of complications. These children present for procedures where an acute exacerbation of their chronic illness-termed Pulmonary Hypertensive (PH)crisis, can occur, often resulting in death if not detected and managed expeditiously. Unfortunately there is little data and no consensus in the pediatric literature on how PH crisis should be managed. \--------------------------------------------------------------------------------

Timeline

Start
2012-01
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 0.5 ug/kg
Subject Epinephrine Other / unclassified 1 ug/kg
Subject Phenylephrine Small molecule 1 ug/kg
Subject Vasopressin Peptide 1 ug/kg